IP Library Granted Patent US 8,603,816
Granted Patent B2
US 8,603,816 · App. 13/611,274 · Granted Dec 10, 2013

SMAC mimetic

Inventors: Stephen M. Condon (Glenmoore, PA); Yijun Deng (Dresher, PA); Matthew G. LaPorte (Honeybrook, PA); Susan R. Rippin (Wilmington, DE)
Assignee: TetraLogic Pharmaceuticals Corp.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,603,816
App. No.
13/611,274
Granted
Dec 10, 2013
Kind
B2
Abstract

A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Claims (10)

1. A method of treating cancer in a mammal in need thereof that comprises internally administering to the animal an effective amount of Compound 15 of the following formula:

where R5 is —CH 2 CH 3 .

2. The method of claim 1 wherein the cancer is a cancer selected from the group consisting of: sarcomas, bladder cancer, ovarian cancer, breast cancer, brain cancer, pancreatic cancer, colon cancer, blood cancer, skin cancer, lung cancer, and bone cancer.

3. The method of claim 1 wherein the cancer is selected from colorectal cancer, renal carinoma, ovarian carcinoma, pancreatic carcinoma, prostate carcinoma, breast carcinoma, melanoma, gliobastoma, acute myeloid leukemia, small cell lung cell carcinoma, non-small cell lung carcinoma, rhabdomyosarcoma, and basal cell carcinoma.

4. A method for inducing apoptosis in a cancer cell comprising contacting the cell with Compound 15 of the following formula:

where R5 is —CH 2 CH 3 or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 that comprises administering Compound 15 in combination with a second cancer therapy selected from radiation, chemotherapy, immunotherapy, photodynamic therapy, and combinations thereof.

6. The method of claim 2 that comprises administering Compound 15 in combination with a second cancer therapy selected from radiation, chemotherapy, immunotherapy, photodynamic therapy, and combinations thereof.

7. The method of claim 3 that comprises administering Compound 15 in combination with a second cancer therapy selected from radiation, chemotherapy, immunotherapy, photodynamic therapy, and combinations thereof.

8. The method of claim 4 that comprises administering Compound 15 in combination with a second cancer therapy selected from radiation, chemotherapy, immunotherapy, photodynamic therapy, and combinations thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2021
From: CONDON, STEPHEN M; DENG, YIJUN; LAPORTE, MATTHEW G; RIPPIN, SUSAN R
To: TETRALOGIC PHARMACEUTICALS CORP.
Reel/Frame 056348/0283 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME PREVIOUSLY RECORDED AT REEL: 047436 FRAME: 0203. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 25, 2021
From: TETRALOGIC BIRINAPANT UK LTD.
To: MEDIVIR AB
Reel/Frame 056392/0690 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2018
From: TETRALOGIC BIRINAPANT UK
To: MEDIVIR AB
Reel/Frame 047436/0203 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2015
From: TETRALOGIC PHARMACEUTICALS CORPORATION
To: TETRALOGIC BIRINAPANT UK LTD
Reel/Frame 036264/0713 →
Continuity (3)
Division 12819221 · Jun 20, 2010
Provisional Application 61222668 · Jul 2, 2009
Related Publication 20130012564A1 · Jan 10, 2013